This is calculated as R&D expenditures divided by total assets. R&D expense is not always broken out in a company's financials, however, so this value may be n/a in those cases.
Like R&D / Sales, this is a measure of R&D intensity. It is useful in comparing the effectiveness of R&D expenditures between companies in the same industry. It is less obvious across industries - for example, pharmaceuticals and software companies tend to spend a lot on R&D while consumer product companies spent less.
Ticker | Name | R&D to Assets | StockRank™ |
---|---|---|---|
PNK:ALRT | ALR Technologies Inc | 217604.23 | 9 |
PNK:BZYR | Burzynski Research Institute Inc | 49079.44 | 6 |
PNK:PLYZ | Plyzer Technologies Inc | 5559.55 | 15 |
NAQ:IKT | Inhibikase Therapeutics Inc | 3398.94 | 1 |
PNK:RAEWF | Pima Zinc | 2770.1 | 41 |